Volatility Shares Trust 2x Ether ETF

Direxion Daily TSLA Bull 1.5X Shares

iShares Ethereum Trust ETF

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Gold Miners Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

Global X Silver Miners ETF

United States Natural Gas

VanEck Vectors Junior Gold Miners ETF

Guggenheim Solar ETF

T-REX 2X Inverse Tesla Daily Target ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily Gold Miners Bear 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

GraniteShares 1.5x Long Coinbase Daily ETF

Altimmune Inc. Common Stock

Direxion Daily S&P Biotech Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares UltraShort Silver

Nuvve Holding Corp. Common Stock

Siyata Mobile Inc. Common Shares

Shuttle Pharmaceuticals Holdings Inc. Common Stock

Zapp Electric Vehicles Group Limited Ordinary Shares

ZK International Group Co. Ltd Ordinary Share

TTEC Holdings Inc. Common Stock

nLIGHT Inc. Common Stock

SCWorx Corp. Common Stock

Rumble Inc. Class A Common Stock

Insulet Corporation Common Stock

Twin Vee PowerCats Co. Common Stock

Theriva Biologics Inc. Common Stock

MicroAlgo Inc. Ordinary Shares

TeraWulf Inc. Common Stock

Affirm Holdings Inc. Class A Common Stock

Classover Holdings Inc. Class B Common Stock

Akamai Technologies Inc. Common Stock

SoundHound AI Inc Class A Common Stock

NextNav Inc. Common Stock

Peloton Interactive Inc. Class A Common Stock

Click here to get full coverage on Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result - Yahoo Finance

Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result  Yahoo Finance

Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result - Yahoo Finance

Click here to get full coverage on Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Nasdaq

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline  Nasdaq

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Nasdaq

Click here to get full coverage on Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41%  simplywall.st

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st

Click here to get full coverage on Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025  Business Wire

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire

Click here to get full coverage on 1st patients dosed in study of inhaled CF treatment ARCT-032 - Cystic Fibrosis News Today

1st patients dosed in study of inhaled CF treatment ARCT-032  Cystic Fibrosis News Today

1st patients dosed in study of inhaled CF treatment ARCT-032 - Cystic Fibrosis News Today

Click here to get full coverage on Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - BioSpace

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1  BioSpace

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - BioSpace

Click here to get full coverage on Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals - TipRanks

Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals  TipRanks

Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals - TipRanks

Click here to get full coverage on Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet  simplywall.st

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Click here to get full coverage on Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress - Business Wire

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress  Business Wire

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress - Business Wire

Click here to get full coverage on Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ...  Yahoo Finance

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance

Click here to get full coverage on High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st

High Growth Tech Stocks To Watch In The US April 2025  simplywall.st

High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st

Click here to get full coverage on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know  Yahoo Finance

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Click here to get full coverage on Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - simplywall.st

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results  simplywall.st

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - simplywall.st

Click here to get full coverage on Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance

Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers  Yahoo Finance

Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance

Click here to get full coverage on Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Yahoo Finance

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy?  Yahoo Finance

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Yahoo Finance

Click here to get full coverage on Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For  Yahoo Finance

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Click here to get full coverage on Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial - Business Wire

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial  Business Wire

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial - Business Wire

Click here to get full coverage on FDA clears Phase 2 trial of ARCT-032, inhaled mRNA therapy for CF - Cystic Fibrosis News Today

FDA clears Phase 2 trial of ARCT-032, inhaled mRNA therapy for CF  Cystic Fibrosis News Today

FDA clears Phase 2 trial of ARCT-032, inhaled mRNA therapy for CF - Cystic Fibrosis News Today

Click here to get full coverage on Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future - Nasdaq

Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future  Nasdaq

Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future - Nasdaq

Click here to get full coverage on Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha

Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ)  Seeking Alpha

Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha

Click here to get full coverage on BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation - Nasdaq

BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation  Nasdaq

BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation - Nasdaq

Click here to get full coverage on Phase 2 trial possible in ARCT-032, inhaled mRNA therapy for CF - Cystic Fibrosis News Today

Phase 2 trial possible in ARCT-032, inhaled mRNA therapy for CF  Cystic Fibrosis News Today

Phase 2 trial possible in ARCT-032, inhaled mRNA therapy for CF - Cystic Fibrosis News Today

Click here to get full coverage on (PDF) Safety and immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine - ResearchGate

(PDF) Safety and immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine  ResearchGate

(PDF) Safety and immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine - ResearchGate

Click here to get full coverage on Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com

Long Term Trading Analysis for (ARCT)  news.stocktradersdaily.com

Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com

Click here to get full coverage on ARCT-032, therapy for all with CF, showing safety in Phase 1 trial - Cystic Fibrosis News Today

ARCT-032, therapy for all with CF, showing safety in Phase 1 trial  Cystic Fibrosis News Today

ARCT-032, therapy for all with CF, showing safety in Phase 1 trial - Cystic Fibrosis News Today

Click here to get full coverage on Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus

Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News  GuruFocus

Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus

Click here to get full coverage on Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics? - RTTNews

Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics?  RTTNews

Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics? - RTTNews

Click here to get full coverage on Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - Business Wire

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress  Business Wire

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - Business Wire

Click here to get full coverage on ARCT stock touches 52-week low at $8.56 amid market challenges - Investing.com

ARCT stock touches 52-week low at $8.56 amid market challenges  Investing.com

ARCT stock touches 52-week low at $8.56 amid market challenges - Investing.com

Click here to get full coverage on Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate  Business Wire

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire

Click here to get full coverage on A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines | npj Vaccines - Nature

A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines | npj Vaccines  Nature

A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines | npj Vaccines - Nature

Click here to get full coverage on Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - Yahoo Finance

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate  Yahoo Finance

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - Yahoo Finance

Click here to get full coverage on Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - BioSpace

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency  BioSpace

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - BioSpace

Click here to get full coverage on ARCT stock touches 52-week low at $11.59 amid market challenges - Investing.com

ARCT stock touches 52-week low at $11.59 amid market challenges  Investing.com

ARCT stock touches 52-week low at $11.59 amid market challenges - Investing.com

Click here to get full coverage on Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - BioSpace

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial  BioSpace

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - BioSpace

Click here to get full coverage on (ARCT) Investment Report - news.stocktradersdaily.com

(ARCT) Investment Report  news.stocktradersdaily.com

(ARCT) Investment Report - news.stocktradersdaily.com

Click here to get full coverage on Cathie Wood's ARK buys ARCT, TXG, and sells VEEV, EXAS stock - Investing.com

Cathie Wood's ARK buys ARCT, TXG, and sells VEEV, EXAS stock  Investing.com

Cathie Wood's ARK buys ARCT, TXG, and sells VEEV, EXAS stock - Investing.com

Click here to get full coverage on Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - Stock Titan

Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production  Stock Titan

Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - Stock Titan

Click here to get full coverage on Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - Stock Titan

Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power  Stock Titan

Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - Stock Titan

Click here to get full coverage on Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - BioSpace

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination  BioSpace

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - BioSpace

Click here to get full coverage on Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate  MSN

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN

Click here to get full coverage on Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus

Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl  GuruFocus

Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus

Click here to get full coverage on Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - Business Wire

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025  Business Wire

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - Business Wire

Click here to get full coverage on Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials - Nature

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials  Nature

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials - Nature

Click here to get full coverage on New Study Results Highlight Efficacy of ARCT-154 sa-mRNA Vaccine Against COVID-19 - Infection Control Today

New Study Results Highlight Efficacy of ARCT-154 sa-mRNA Vaccine Against COVID-19  Infection Control Today

New Study Results Highlight Efficacy of ARCT-154 sa-mRNA Vaccine Against COVID-19 - Infection Control Today

Click here to get full coverage on Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f  GuruFocus

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus

Click here to get full coverage on Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Arcturus Ther - GuruFocus

Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Arcturus Ther  GuruFocus

Sumitomo Mitsui Trust Group, Inc. Reduces Stake in Arcturus Ther - GuruFocus

Click here to get full coverage on Arcturus Therapeutics Q4 and FY 2024 Financial Update - TradingView

Arcturus Therapeutics Q4 and FY 2024 Financial Update  TradingView

Arcturus Therapeutics Q4 and FY 2024 Financial Update - TradingView

Click here to get full coverage on Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements - TipRanks

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements  TipRanks

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements - TipRanks

Click here to get full coverage on Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults - PR Newswire

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults  PR Newswire

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults - PR Newswire

Click here to get full coverage on FDA orphan drug status awarded to inhaled CF therapy ARCT-032 - Cystic Fibrosis News Today

FDA orphan drug status awarded to inhaled CF therapy ARCT-032  Cystic Fibrosis News Today

FDA orphan drug status awarded to inhaled CF therapy ARCT-032 - Cystic Fibrosis News Today

Click here to get full coverage on Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 - The Lancet

Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2  The Lancet

Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 - The Lancet

Click here to get full coverage on New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - PR Newswire

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster  PR Newswire

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - PR Newswire

Arcturus Therapeutics Holdings Inc (ARCT)

Price Chart

Key Statistics

Technicals

About ARCT

Latest News

Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result - Yahoo Finance

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Nasdaq

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st

Advanced Charts

Top Gainers

Top Losers